JP2025509106A5 - - Google Patents

Info

Publication number
JP2025509106A5
JP2025509106A5 JP2024549763A JP2024549763A JP2025509106A5 JP 2025509106 A5 JP2025509106 A5 JP 2025509106A5 JP 2024549763 A JP2024549763 A JP 2024549763A JP 2024549763 A JP2024549763 A JP 2024549763A JP 2025509106 A5 JP2025509106 A5 JP 2025509106A5
Authority
JP
Japan
Prior art keywords
plasmid vector
orf
vector according
protein
orf encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024549763A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509106A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/TH2023/000003 external-priority patent/WO2023182948A1/en
Publication of JP2025509106A publication Critical patent/JP2025509106A/ja
Publication of JP2025509106A5 publication Critical patent/JP2025509106A5/ja
Pending legal-status Critical Current

Links

JP2024549763A 2022-03-21 2023-03-21 タンパク質発現を増強するための、配列内リボソーム進入部位(IRES)、プラスミドベクター及び環状mRNA Pending JP2025509106A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
TH2201001686 2022-03-21
TH2201001686 2022-03-21
PCT/TH2023/000003 WO2023182948A1 (en) 2022-03-21 2023-03-21 Internal ribosome entry site (ires), plasmid vector and circular mrna for enhancing protein expression

Publications (2)

Publication Number Publication Date
JP2025509106A JP2025509106A (ja) 2025-04-11
JP2025509106A5 true JP2025509106A5 (cg-RX-API-DMAC7.html) 2026-04-01

Family

ID=86054332

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024549763A Pending JP2025509106A (ja) 2022-03-21 2023-03-21 タンパク質発現を増強するための、配列内リボソーム進入部位(IRES)、プラスミドベクター及び環状mRNA

Country Status (6)

Country Link
US (1) US20250243507A1 (cg-RX-API-DMAC7.html)
EP (1) EP4496598A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025509106A (cg-RX-API-DMAC7.html)
CN (1) CN118871134A (cg-RX-API-DMAC7.html)
AU (1) AU2023240827A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023182948A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4680595A2 (en) 2023-03-15 2026-01-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2026006644A1 (en) * 2024-06-26 2026-01-02 Emervax, Inc. Circular mrna yellow fever vaccine
WO2026006593A1 (en) 2024-06-28 2026-01-02 Orna Therapeutics, Inc. Synthetic internal ribosome entry sites
CN119464284B (zh) * 2024-09-29 2026-02-13 复旦大学附属肿瘤医院 一种用于免疫细胞高效蛋白表达的环形rna疫苗平台及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2746803T3 (es) 2013-05-15 2020-03-06 Robert Kruse Traducción intracelular de ARN circular
CN112399860B (zh) 2018-06-06 2024-08-16 麻省理工学院 用于在真核细胞中翻译的环状rna
JP7686574B2 (ja) 2019-05-22 2025-06-02 マサチューセッツ インスティテュート オブ テクノロジー 環状rna組成物及び方法
WO2021046243A2 (en) * 2019-09-03 2021-03-11 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
US20240245805A1 (en) * 2020-03-20 2024-07-25 Orna Therapeutics, Inc. Circular rna compositions and methods
AU2021269137A1 (en) * 2020-05-08 2022-12-15 Orna Therapeutics, Inc. Circular RNA compositions and methods
CN116322788A (zh) * 2020-05-19 2023-06-23 奥纳治疗公司 环状rna组合物和方法
AU2021275223A1 (en) * 2020-05-20 2023-02-02 Flagship Pioneering Innovations Vi, Llc. Coronavirus antigen compositions and their uses
CN116194581A (zh) * 2020-07-01 2023-05-30 艾勒维生技公司 使用环状rna进行细胞重编程的组合物和方法
CN116635525A (zh) * 2020-08-21 2023-08-22 北京大学 环状rna疫苗及其使用方法
IL300947A (en) * 2020-09-03 2023-04-01 Flagship Pioneering Innovations Vi Llc Immunogenic compositions and uses thereof
WO2022241029A1 (en) * 2021-05-11 2022-11-17 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
CN115404240A (zh) * 2021-05-28 2022-11-29 上海环码生物医药有限公司 制备环形rna的构建体、方法及其用途
AU2022288705A1 (en) * 2021-06-10 2023-12-07 Orna Therapeutics, Inc. Circular rna compositions and methods
CN115702940A (zh) * 2021-08-05 2023-02-17 苏州科锐迈德生物医药科技有限公司 包含环状rna分子的制剂在制备治疗肿瘤的药物中的应用

Similar Documents

Publication Publication Date Title
Northemann et al. Structure of the rat interleukin 6 gene and its expression in macrophage-derived cells
JP4307775B2 (ja) Csf−1インヒビターの使用
Lutfalla et al. A new member of the cytokine receptor gene family maps on chromosome 21 at less than 35 kb from IFNAR
JP2006506469A5 (cg-RX-API-DMAC7.html)
WO1997016539A1 (en) Recombinant sendai virus
JPH08506479A (ja) C型肝炎ウイルス関連疾患の治療のための組成物および方法
CN111386344A (zh) 功能性核酸分子及其用途
JP2004501646A5 (cg-RX-API-DMAC7.html)
CN113249380B (zh) 靶向covid-19新冠病毒的反义寡核苷酸、natac嵌合分子及其应用
EP0784094B1 (en) Ribozyme -snRNA chimeric molecules having a catalytic activity for nuclear RNAs
JP2024513907A5 (cg-RX-API-DMAC7.html)
JP4789095B2 (ja) ウイルムス腫瘍遺伝子(wt1)に対する発現阻害物質を含んで成る固形腫瘍治療剤
Gitlin et al. Transcriptional activation of the human T-lymphotropic virus type I long terminal repeat by functional interaction of Tax1 and Ets1
US20060171924A1 (en) Bidirectional promoters for small RNA expression
Uchiumi et al. Characterization of the promoter region of the src family gene lyn and its trans activation by human T-cell leukemia virus type I-encoded p40 tax
WO2000031271A1 (en) Hiv infection inhibitors
JP2006523103A5 (cg-RX-API-DMAC7.html)
CN115806984A (zh) 环状rna及载体和载体的应用
WO2004055035A1 (en) A group of nucleic acid fragments for prevention of hiv infection or aids and the usage thereof
JP2024529930A5 (cg-RX-API-DMAC7.html)
Tsurimoto et al. Multiple initiation sites of DNA replication flanking the origin region of lambda dv genome.
Yonetani et al. Heterogeneous breakpoints on the immunoglobulin genes are involved in fusion with the 5′ region of BCL2 in B‐cell tumors
EP0867514B1 (en) Enhanced protein production method
Yang et al. Cloning, characterization and genomic organization of LCC-1 (scya16), a novel human CC chemokine expressed in liver
CN101250510A (zh) 丙肝病毒特异性核酶M1GS-hcv/C20的构建方法和应用